Anemia and hemodilution – Analysis of a single center cohort based on 2858 Red Cell Mass measurements Par MarcGuevreguian|2021-03-22T19:20:25+01:00juin 25th, 2020| Lire la suite
Illuminating novel biological aspects and potential new therapeutic approaches… Par MarcGuevreguian|2021-03-22T19:55:52+01:00juin 20th, 2020| Lire la suite
Patient Experiences with Avelumab in Treatment‑Naïve Metastatic Merkel Cell Carcinoma Par MarcGuevreguian|2021-03-22T20:38:57+01:00mai 30th, 2020| Lire la suite
Avelumab in patients with previously treated metastatic Merkel cell carcinoma Par MarcGuevreguian|2021-03-22T19:49:58+01:00mai 8th, 2020| Lire la suite
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial Par MarcGuevreguian|2021-03-22T20:32:51+01:00avril 23rd, 2020| Lire la suite
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses Par MarcGuevreguian|2021-03-23T10:34:44+01:00mars 23rd, 2020| Lire la suite
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria Par MarcGuevreguian|2021-03-23T09:42:36+01:00mars 19th, 2020| Lire la suite
Overall survival at 5 years of follow-up in a phase III trial… Par MarcGuevreguian|2021-03-22T20:35:56+01:00mars 11th, 2020| Lire la suite
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma Par MarcGuevreguian|2021-03-22T19:50:27+01:00février 22nd, 2020| Lire la suite
Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report Par MarcGuevreguian|2021-03-22T21:14:24+01:00février 7th, 2020| Lire la suite
